• Shanghai MicroPort MedBot guided for a swing to net profit of RMB 28 million to RMB 40 million for H1 2026.
• Compares with a net loss of RMB 115 million a year earlier; first semi-annual profit.
• Revenue expected to rise about 200% to 230%, led by Toumai robot sales; overseas Toumai revenue seen up over 450%.
• Gross margin forecast to improve by more than 15 percentage points, helped by scale benefits, manufacturing cost cuts, higher consumables mix.
• Operating expense ratio expected to fall as cost controls lifted efficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai MicroPort MedBot Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260722-12253181), on July 22, 2026, and is solely responsible for the information contained therein.